Targeted Therapy for Breast Cancer by Subtype

Targeted therapy for breast cancer depends on the tumour’s biomarkers, the stage and the treatments already given. In hormone receptor-positive, HER2-negative breast cancer, targeted drugs often work alongside hormone therapy. In HER2-positive breast cancer, treatment can directly target the HER2 protein. In triple-negative breast cancer, options such as PARP inhibitors and antibody–drug conjugates can help selected patients, while immunotherapy is a separate treatment option. www.cancer.gov

By Dr Raman Narang, Consultant Medical & Hemato-Oncologist

A pathology report can say that a cancer is both hormone receptor-positive and HER2-positive. That can be confusing when treatment guides describe them as separate groups. In this article, hormone-positive refers to hormone receptor-positive, HER2-negative disease. The HER2-positive section includes cancers that also have hormone receptors. Triple-negative breast cancer, or TNBC, tests negative for all three markers used in this classification: oestrogen receptor (ER), progesterone receptor (PR) and HER2. www.cancer.gov

If you’re weighing surgery first, medicines first or treatment for stage IV disease, this article explains how the subtype helps determine which medicines may be useful.

1. What targeted therapy is used for hormone-positive breast cancer?

For hormone receptor-positive, HER2-negative breast cancer, endocrine therapy, also called hormone therapy, is the foundation of treatment for many patients. It reduces the effect of oestrogen on cancer cells. A separate class of targeted drugs, called CDK4/6 inhibitors, blocks proteins involved in cell division and can be added to endocrine therapy in certain settings. pubmed.ncbi.nlm.nih.gov

In early breast cancer, many patients receive endocrine therapy after surgery. Selected patients with a higher risk of recurrence may also be offered a CDK4/6 inhibitor. Abemaciclib and ribociclib are examples, with different eligibility criteria. The decision about whether to add one is separate from the decision about whether chemotherapy would help. Ask your oncologist what features of your pathology make you eligible, how much benefit is expected and what monitoring the drug would require. pubmed.ncbi.nlm.nih.gov

In metastatic breast cancer, endocrine therapy plus a CDK4/6 inhibitor is a common starting approach when endocrine-based treatment is appropriate. If the cancer grows despite treatment, the next choice depends on which drugs you have already received, how quickly the disease is progressing and whether a test identifies a change that can guide treatment. For example, testing for changes in PIK3CA or ESR1 may help choose a subsequent treatment in selected cases. Before ordering a panel, it is worth asking which result could change the next prescription. annalsofoncology.org

2. How does targeted therapy work for HER2-positive breast cancer?

HER2-positive breast cancer has high levels of the HER2 protein or extra copies of the HER2 gene, as determined by pathology testing. Trastuzumab is a HER2-directed antibody. It is often given with chemotherapy, and pertuzumab may be added in selected situations. If the cancer is also hormone receptor-positive, endocrine therapy can be part of the plan as well. www.cancer.gov

In early or locally advanced HER2-positive breast cancer, the tumour size and lymph node findings help determine the sequence. A smaller, operable tumour may be removed first, with the final pathology guiding treatment afterwards. For higher-risk disease, the team often starts with chemotherapy and HER2-directed treatment before surgery. If invasive cancer remains in the tissue removed at surgery, an antibody–drug conjugate (ADC) may be recommended. An ADC uses an antibody to carry a cancer-killing drug. Trastuzumab emtansine (T-DM1) has been used in this setting, and newer trial evidence and a 2026 US approval support trastuzumab deruxtecan (T-DXd) for defined patients with residual disease. pmc.ncbi.nlm.nih.gov

In metastatic HER2-positive breast cancer, the choice among HER2-directed regimens depends on factors such as previous treatment, when the cancer returned and whether there are brain metastases. Different medicines require different monitoring. For example, the team may check heart function with trastuzumab-based treatment and discuss lung inflammation and which symptoms to report if T-DXd is being considered. annalsofoncology.org

3. Are there targeted treatments for triple-negative breast cancer?

Triple-negative breast cancer has fewer treatment options based on ER, PR and HER2, but other biomarkers can matter. For example, an inherited pathogenic BRCA1 or BRCA2 variant can make a PARP inhibitor an option in defined settings. Olaparib may be considered after standard treatment for eligible patients with high-risk, early HER2-negative breast cancer and an inherited BRCA variant. PARP inhibitors can also be options for selected patients with metastatic HER2-negative disease. These indications can apply to either TNBC or hormone receptor-positive disease. www.cancer.gov

For high-risk early TNBC, pembrolizumab may be given with chemotherapy before surgery and continued after surgery in eligible patients. Pembrolizumab is immunotherapy. Eligibility for this early-stage approach does not require a positive PD-L1 result. In metastatic TNBC, by contrast, PD-L1 testing can help determine whether a pembrolizumab-based first treatment is appropriate. www.cancer.gov

In unresectable or metastatic TNBC, an ADC such as sacituzumab govitecan can be an option. Its role has expanded beyond later lines in some jurisdictions. In June 2026, the US FDA approved specific first-line uses based on whether a patient is eligible for checkpoint immunotherapy and, for the pembrolizumab combination, whether the tumour meets the PD-L1 threshold. A US approval describes use in the US. For treatment in India, ask your team to confirm the applicable local indication, availability and expected out-of-pocket cost. annalsofoncology.org

4. Which test results could change my treatment plan?

What I look for clinically

I start with the original ER, PR and HER2 results and check which decision we need to make now. If the HER2 report reads IHC 2+, I look for the follow-up ISH result, which checks for extra copies of the HER2 gene. If the cancer has returned at a distant site and a biopsy is safe and feasible, testing the new sample can matter because the receptor results sometimes change. I also review prior medicines and side effects before deciding whether an additional test would affect the next step. www.cancer.gov

If–then map for the treatment discussion

If your report and stage show…Then ask your oncology team…
Early hormone receptor-positive, HER2-negative diseaseIs endocrine therapy enough, or does my recurrence risk justify discussing a CDK4/6 inhibitor?
Metastatic hormone receptor-positive, HER2-negative diseaseIs endocrine therapy plus a CDK4/6 inhibitor appropriate now? If I’ve already received one, which test could guide the next choice?
HER2-positive diseaseWhich HER2-directed medicine fits my stage and previous treatment? Could the findings at surgery change the plan?
Triple-negative diseaseWould inherited BRCA testing, PD-L1 testing or a review of the exact HER2 score change my options at this stage?

The tests that matter depend on the stage and the treatment decision in front of you. Read more about [how precision oncology uses biomarker testing](/precision-oncology/). www.cancer.gov

Patient checklist before the consultation

  • Bring the full biopsy and surgery pathology reports, including any addenda.
  • Find the exact ER, PR and HER2 results, including the HER2 IHC score and any ISH result.
  • Bring any inherited genetic test, tumour sequencing or PD-L1 report already available.
  • List previous cancer medicines, when you received them and why each was stopped.
  • Ask which test result makes you eligible for the proposed medicine and what benefit it is expected to offer at your stage.
  • Ask about monitoring, likely visit frequency and the estimated cost of treatment and tests.

5. What else should I know before starting targeted therapy?

Is targeted therapy the same as chemotherapy?

Targeted therapy acts on a specific protein or pathway. Conventional chemotherapy affects processes involved in cell growth and division. Some treatments combine the two approaches. For instance, an ADC uses a targeted antibody to deliver a cancer-killing payload, and trastuzumab can also be given alongside conventional chemotherapy. www.cancer.gov

Is HER2-low breast cancer the same as HER2-positive breast cancer?

HER2-low generally describes a tumour with an IHC score of 1+, or 2+ with a negative ISH result. It falls within the HER2-negative classification for conventional HER2-positive treatment decisions. The exact score may still matter when considering certain ADCs in eligible patients with advanced disease. www.cancer.gov

Does a positive BRCA result mean I should receive a PARP inhibitor?

Ask whether the report shows a confirmed inherited pathogenic variant and whether your stage and treatment history fit the indication. An inherited BRCA finding can also have implications for relatives, which can be discussed with a genetics professional. www.cancer.gov

Can targeted therapy replace breast surgery or radiation?

In early or locally advanced breast cancer treated with the aim of cure, targeted medicines may be given before or after surgery. Surgery and radiation are planned according to the original extent of disease, the operation and the response to treatment. In stage IV disease, medicines usually play the main role, with radiation or surgery used for specific reasons. See the [stage-wise guide to breast surgery, chemotherapy and radiation](/breast-cancer-treatment-delhi/). www.cancer.gov

Closing perspective

When a targeted medicine is proposed, ask which finding makes it relevant, what it is expected to achieve now and what would change the next step. If reports disagree about HER2 status, or if two teams recommend different medicines after surgery or progression, a [focused second opinion on your treatment plan](/second-opinion-cancer/) can help identify the result driving that difference.

This article is for general education. Treatment eligibility and sequencing require an individual review of your pathology, prior treatment and overall health.

References for editorial verification


Related reads

Breast cancer Treatment Delhi

No Lump, No Pain

Can we skip chemotherapy ?

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top